Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells target Stomach-Lining tumors in colorectal cancer

NCT ID NCT07247396

Recruiting now Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Dec 02, 2025 · Last updated May 08, 2026 · Updated 26 times

Summary

This early-phase study tests a new immunotherapy using a patient's own immune cells, engineered to recognize a protein called CEA on cancer cells. The treatment is given after surgery to remove visible tumors in the abdomen. The goal is to find a safe dose and see if it can delay cancer regrowth in people with advanced colorectal cancer that has spread to the lining of the belly.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERITONEAL METASTASES FROM COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Second Affiliated Hospital of Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, 310017, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

PERITONEAL METASTASES FROM COLORECTAL CANCER